Isatuximab approved in the EU for the treatment of transplant-eligible MM
The European Commission has approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly
Multiple Myeloma
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML
A phase 2 study found that eprenetapopt plus azacitidine induced responses in patients with TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This
Multiple Myeloma
Eque-cel receives Orphan Drug status for myeloma treatment in South Korea
South Korea’s Ministry of Food and Drug Safety (MFDS) granted Orphan Drug Designation to equecabtagene autoleucel (Fucaso; eque-cel) for adults with relapsed or
Lymphoma
Aggressive B-Cell Lymphomas
News
FDA rejects glofitamab-GemOx sBLA in DLBCL
The US Food and Drug Administration (FDA) denied the supplemental Biologics License Application (sBLA) for glofitamab combined with gemcitabine and oxaliplatin (GemOx) for
Leukemia
Acute Myeloid Leukemia
News
Pathways & Perspectives with Alice Mims, MD
Meet Alice Mims, MD, a professor at The Ohio State University and senior medical director of the BeatAML study. Dr. Mims discusses venetoclax’s
18-IMCL
Meetings / Conferences
Income tied to survival outcomes in patients with DLBCL
A Finnish study found that patients with diffuse large B-cell lymphoma (DLBCL) who have low income levels have significantly worse survival outcomes.
Cellular Therapy
Multiple Myeloma
A third of myeloma patients in remission more than 5 years after cilta-cel treatment
Long-term follow-up from the CARTITUDE-1 study showed that 33% of heavily pretreated patients with multiple myeloma (MM) were in remission for 5 or
Ambassador Program
News
Society Updates
SOHO regional meeting in Brazil delivers again
SOHO President Phillip Scheinberg, MD, PhD, head of the Division of Hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, wrote
18-IMCL
Vitamin D supplementation does not improve DLBCL outcomes
A study found that low baseline vitamin D is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL); however, supplementation
News
Society Updates
SOHO President Dr. Scheinberg drops hint on 2025 surprise
Phil Scheinberg, MD, PhD, chief of hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, shares his first impressions of